On February 21, 2018 Nippon Kayaku Co., Ltd. (Head Office: Tokyo, President: Masanobu Suzuki, "Nippon Kayaku") reported the initiation of a phase 2 clinical study of NK105 in breast cancer (Press release, Nippon Kayaku, FEB 21, 2018, View Source;sid=40697&code=4272 [SID1234524075]).

This study is a randomized trial comparing the same dosage of weekly administration of NK105 versus paclitaxel in terms of efficacy and safety in patients with advanced or recurrent breast cancer.

With the goal of early launch of this product, we expect to make an even greater contribution to cancer patients, their families and medical professionals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About NK105
NK105 is a novel DDS (Drug Delivery System) formulation encapsulating active ingredient paclitaxel in macromolecular micelles.